Undernutrition is common among tuberculosis (TB) patients. The objective of this study was to assess the effect of multimicronutrient supplementation during TB treatment on weight, body composition, and handgrip strength. A total of 865 patients with smear-positive (PTB+) or -negative (PTB-) pulmonary TB were randomly allocated to receive a daily biscuit with or without multi-micronutrients for 60 d during the intensive phase of TB treatment. Weight, arm fat area, arm muscle area, and handgrip strength were assessed at baseline and after 2 and 5 mo. At 2 mo, the multi-micronutrient supplementation led to a higher handgrip gain (1.22 kg; 95% CI = 0.50, 1.94; P = 0.001) but had no effects on other outcomes. The effects of multimicronutrient supplementation were modified by HIV infection (P-interaction = 0.002). Among HIV-patients, multimicronutrient supplementation increased weight gain by 590 g (95% CI = 240, 1210; P = 0.07) and handgrip strength by 1.6 kg (95% CI = 0.78, 2.47; P , 0.001), whereas among HIV+ patients, it reduced weight gain by 1440 g (95% CI = 290, 2590; P = 0.002) and had no effect on handgrip strength (0.07 kg; 95% CI = 21.30, 1.46; P = 0.91). The reduced weight gain among HIV+ patients receiving multi-micronutrient supplementation seemed to be explained by a higher proportion of patients reporting fever. At 5 mo, the effects on weight were sustained, whereas there was no effect on handgrip strength. In conclusion, multimicronutrient supplementation given as a biscuit is beneficial among HIV2 PTB patients and may be recommended to TB programs. More research is needed to develop an effective supplement for HIV+ PTB patients.
Introduction
Undernutrition is common among tuberculosis (TB) 11 patients (1) (2) (3) (4) and is associated with unfavorable treatment outcomes (5) (6) (7) (8) . Consequently, nutritional support should be integrated in TB case management, although the available evidence is inadequate (5, (9) (10) (11) (12) .
A recent randomized trial among sputum-positive pulmonary TB patients (PTB+) in Tanzania found that at the end of 7 mo of multi-micronutrient supplementation, there was an increase of 2.4 kg among patients receiving both zinc and other micronutrients and a 70% reduction in mortality among those co-infected with HIV (HIV+) (7) . Based on these findings, we conducted 2 trials to further examine the effects of nutritional support on weight, body composition, and handgrip strength. Among PTB+/HIV+ patients, we assessed the effects of adding energy-protein to the multi-micronutrient supplement previously found to improve survival (7) , whereas among sputumnegative pulmonary TB (PTB2)/HIV2, PTB2/HIV+, and PTB+/HIV2 patients, the effects of multi-micronutrient supple-mentation were assessed. Here we report the results of the latter trial.
Methods
Study area and participants. The study was conducted from April 2006 to March 2009 in Mwanza city, Tanzania. Study participants were recruited from 4 TB clinics that cater to both urban and suburban populations of the city. New or relapse TB patients (13) about to start treatment were enrolled in the study after giving written informed consent if they were PTB+ or PTB2, and residents of Mwanza city. Patients with extra-pulmonary TB or terminal illness or who were pregnant or aged , 15 y were excluded as were PTB+ patients with HIV co-infection who were included in a concurrent trial. Consequently, patients included in this study were PTB+/HIV2, PTB2/HIV+, or PTB2/ HIV2. The diagnosis of TB followed established guidelines (14, 15) . Briefly, all those suspected of having TB were asked to bring 3 sputum samples for microscopy (16) and were asked to do a chest X-ray as appropriate. Patients were classified as PTB+ if 2 samples tested positive or one sample tested positive and a chest X-ray was suggestive of TB, and as PTB2 if all the samples were negative but the chest X-ray was suggestive of TB and there was nonresponse to a course of broad-spectrum antibiotics. After diagnosis, all patients were started on a standardized TB treatment for 6-8 mo based on existing national guidelines (13, 17) .
Study design. This was a randomized, double-blind, controlled trial assessing the effect of a multi-micronutrient supplement, given as a biscuit, among TB patients on weight, arm fat area, arm muscle area, and handgrip strength. Patients were randomized to receive an energyprotein biscuit with or without additional multiple-micronutrients daily for 60 d during the first 2 mo of TB treatment. The control biscuit weighed 30 g and contained 4.5 g of protein, 615 kJ of energy, 120 mg phosphorous, 120 mg calcium, 36 mg magnesium, 70 mg sodium, 150 mg potassium, and traces (,1 mg) of iron and zinc. The experimental biscuit had the same weight and content of protein, energy, phosphorous, calcium, magnesium, sodium, potassium, and iron as the control biscuit, but in addition, it contained: vitamin A (retinyl palmitate), 1.5 mg; thiamin (thiamine hydrochloride), 20 mg; riboflavin, 20 mg; vitamin B-6 (pyridoxine hydrochloride), 25 mg; vitamin B-12 (cyanocobalamin), 50 mg; folic acid, 0.8 mg; niacin (niacinamide), 40 mg; vitamin C (ascorbic acid), 200 mg; vitamin E (dl-a-tocopherol acetate), 60 mg; vitamin D (cholecalciferol), 5 mg; selenium (sodium selenite), 0.2 mg; copper (copper gluconate), 5 mg; and zinc (zinc acetate), 30 mg. The products were manufactured by Compact for this trial based on modification of a commercial product as suggested by the researchers. The experimental biscuit had a high micronutrient content, because TB patients often have micronutrient deficiencies (18) and increased requirements during recovery when regaining~7-10 kg of body weight (19, 20) . The multimicronutrient content was similar to what was previously found beneficial among TB patients (7) . The amount of zinc given, however, was reduced from 45 to 30 mg, because absorption of zinc delivered through biscuits might be higher compared to zinc given through a tablet, which would normally be taken with a cereal-based diet.
Allocation to treatment arms followed a computer-generated randomization sequence using permuted blocks of 10. The random sequence was used by a designated research staff member who was not involved in any clinical work in TB clinics to arrange and label the supplement packs with identity numbers ranging from 1 to 1500. During the study, the randomization sequence and code were kept in a safe cabinet and were accessible only to the designated research staff. Recruitment of study patients was done by TB clinic staff. Then the same designated research staff assigned the recruited patient an identity number and sent the corresponding nutritional supplement pack to the respective clinic. TB clinic staff was responsible for dispensing the supplements, monitoring, and keeping the intake records. Both control and experimental supplements were of the same size and color but had slightly different taste and were wrapped in gray-colored paper box with 6 bars each. Thus, neither TB clinic staff nor patients were aware of the micronutrient content of the supplements. The supplements were provided through the national TB program alongside TB drugs. Patients recruited prior to October, 2006 ingested supplements under TB clinic supervision (13) . However, beginning October 1, 2006, all new TB patients took their supplements at home, following a policy change that allowed new patients to take their drugs at home under a home-based supervisor (17) .
Study outcomes. The primary outcomes were weight gain at 2 and 5 mo, i.e. at the end of the supplementation period and 3 mo after. Secondary outcomes were gain in arm fat area, arm muscle area, and handgrip strength at 2 and 5 mo. The rationale for the choice of the primary outcome was that weight gain is an indicator of clinical response (21, 22) during TB treatment and is associated with lower mortality (7) and decreased risk of recurrence (23) . The use of arm fat and muscle area, which are proxies for fat and lean mass as secondary outcomes, was due to the fact that an increase in lean mass independent of body weight is associated with improved health, functional outcomes, and survival in some patient groups (24) (25) (26) . In contrast, excessive increment of fat mass during TB recovery may confer little functional benefit and may increase the risk of metabolic syndrome (27) . As a measure of physical capability, handgrip strength was included as an outcome, because it is an important marker of health status, including survival (28) .
Data collection. Socio-demography and morbidity (history of respiratory symptoms and fever within previous 2 wk) data were collected using questionnaires and HIV testing and CD4 counting were done as previously described (29) . Weight was determined to the nearest 0.1 kg using a digital scale (Seca) and height was determined to the nearest 0.1 cm using a height board. Mid-upper arm circumference was determined to the nearest 0.1 cm using a tape measure, and triceps skinfold thickness was determined to the nearest 0.1 mm using Harpenden caliper on the left arm. Measurements were taken in duplicate, with the mean values reported. Based on midupper arm circumference and triceps skinfold thickness measurements, arm muscle area and arm fat area were calculated as previously described (30) and BMI was calculated as weight (kg)/(height (m)) 2 (31) . Handgrip strength was determined to the nearest 0.1 kg using a digital dynamometer (Takei Scientific Instruments). All measurements were done at recruitment and repeated at the end of mo 2 and 5. Before October 2006, the intake of supplements was recorded directly after supervised ingestion. From October 2006 onwards, patients who choose to take supplements at home were asked to record the intake of supplements using a log designed for this purpose, which was handed to the TB clinic for updating the intake records, when the patient came to collect the next supplements pack. Intake of at least 80% of the supplements was regarded as adequate compliance.
Sample size estimation and power considerations. We planned to recruit 1500 PTB patients for this trial. In a previous trial, we found that the SD for weight gain in the first 2 mo was 3.5 kg. Therefore, we would be able to detect a $0.55-kg weight gain difference with 80% power and 5% significance level while allowing for 15% loss to follow-up. With ;860 patients, and assuming two-thirds were HIV2 and one-third were HIV+ and 10% loss to follow-up, we would be able to detect an overall 0.7-kg weight gain difference between the 2 groups, and 0.8 kg and 1.3 kg among HIV2 and HIV+ patients, respectively.
Statistical analysis. Data were double entered in EpiData (EpiData Association) and analyzed using Stata/IC version 10.0 (StataCorp). Normal probability plots were used to assess normality of continuous variables. Differences in categorical and continuous variables between groups were tested using chi-square test and t test, respectively. Linear regression was used to adjust for potential confounders and to test for interactions with HIV status, sex, sputum microscopy results, mode of supplementation (clinic-vs. home-based supplementation), and antiretroviral use. Where interaction was detected for the primary outcome, the effects of the intervention were assessed by the level of the effect modifier. Analysis was done on an intention-to-treat basis. Data on effects of the intervention are presented as mean (95% CI). P-values , 0.05 were considered significant. 
Results
Of 2355 TB patients screened at TB clinics during the recruitment period, 38.8% (913) were eligible, of which 94.7% (865) consented to participate in the trial and were randomized (Supplemental Fig. 1 ). Of those ineligible, 59.8% (863/1442) were nonresidents, 22.9% (330/1442) had extra-pulmonary TB, and the remaining 17.3% (249/1442) were aged ,15 y, terminally ill, or pregnant. Of the 865 recruited, the mean age was 37 (range 15-89) y, BMI was 18.9 6 3.0 kg/m 2 , and 37% were females. About 93.4% of patients were new TB cases, 56% had PTB+, 28% tested positive for HIV of which 11% (27/245) of the HIV+ patients were on antiretroviral therapy. Randomization resulted in equal distribution of baseline characteristics ( Table 1) . During follow-up for 2 and 5 mo, the loss to follow-up was 10.2%and 18.0%, respectively. However, the proportions lost to follow-up did not differ between multi-micronutrient and control arms at either time point [11 1 Values are mean 6 SD or n (%). 2 Patients were asked whether they had been consuming any form of alcohol prior to TB diagnosis. 3 Grading done according to the International Union Against Tuberculosis and Lung Disease guidelines (15) . 4 Eight values are missing in the multi-micronutrient arm and 9 in the control arm. 5 Computed for HIV+ patients only. Multi-micronutrient supplementation did not have any effect on weight, arm fat and arm muscle area at 2 and 5 mo ( Table 2) . However, at 2 mo it led to a 1.2-kg (95% CI = 0.50, 1.94; P = 0.001) higher increase in handgrip strength, but this was not sustained at 5 mo (Table 2) . At 2 mo, there was an interaction between multi-micronutrient supplementation and HIV infection for weight (P-interaction = 0.002), which was explained by a 590-g (95% CI = 240, 1210; P = 0.07) greater increase among HIV2 patients and a 1440-g (95% CI = 290, 2590; P = 0.02) lower increase among those who were HIV co-infected (Table  3) . Similarly, multi-micronutrient supplementation led to a 1.6-kg (95% CI = 0.78, 2.47; P = , 0.001) higher handgrip strength gain among HIV2 patients, whereas there was no effect among those co-infected with HIV (0.07 kg; 95% CI = 21.30, 1.46; P = 0.91) (P-interaction = 0.06) ( Table 3) . At 5 mo, the interaction with HIV for weight persisted (P-interaction = 0.001) in that multi-micronutrient supplementation led to a 770-g (95% CI = 60, 1540; P = 0.04) higher weight gain among HIV2 patients, but to a 1910-g (95% CI = 400, 3410; P = 0.01) lower weight gain among those who were HIV co-infected. At both 2 and 5 mo, the changes seemed to be mainly due to fat rather than lean mass, although the differences were not significant (Table 3) . However, the interaction between multi-micronutrient supplementation and HIV for handgrip strength was not sustained (Pinteraction = 0.27) ( Table 3) . In an exploratory analysis, we found that at both 2 and 5 mo follow-up, there were more patients in the multi-micronutrient arm who reported a history of fever within the previous 2 wk in the HIV+ subgroup [28.9% (28/97) vs. 15.4% (16/104); P = 0.02 and 27.8% (25/90) vs. 13.3% (13/98); P = 0.01, respectively]. However, this was not associated with a lower CD4 count (26.1 cells/mL; 95% CI = 2118.4, 106.1; P = 0.91 and 0.2 cells/mL; 95% CI: 2180.7, 181.2; P = 0.99, respectively). Among HIV2 patients, the proportion with reported fever did not differ between those in the 
The percentage of patients with adequate compliance was higher during the period when supplements were taken in clinics compared to when they were taken mainly at home (95.5 vs. 89.7%; P = 0.02). However, in both periods, the proportions of patients with adequate compliance did not differ between the study arms (P = 0.97 and P = 0.46, respectively). Furthermore, in both HIV2 and HIV+ subgroups, supplement compliance was not different between the study arms (P = 0.44 and P = 0.94, respectively). None of the estimates were confounded or modified by sex, baseline microscopy results, mode of supplementation, or antiretroviral use.
Discussion
In this randomized trial, we found that multi-micronutrient (including zinc) supplementation, given as a biscuit during the first 2 mo of TB treatment, led to a greater increase in weight and handgrip strength among HIV2 patients, but had no or even negative effects among those with HIV infection.
The 0.6-kg effect on weight gain at 2 mo was similar to the findings of the earlier trial (32), although only marginally significant and confined to HIV2 patients, i.e. either PTB +/HIV2 or PTB2/HIV2 patients. The effect on weight gain was maintained at 5 mo, i.e. 3 mo after the end of supplementation. At both 2 and 5 mo, changes in weight seemed to be mainly accompanied by changes in arm fat rather than arm muscle area. Thus, although arm fat and arm muscle area are only proxies for fat and lean mass, respectively, this finding may suggest that accrual of lean mass was not optimal. This could be due to the acute phase response that tends to favor accrual of fat over lean mass during early recovery (33) . This may imply that supplementation with zinc, which is important in the synthesis of DNA, cell division, and protein synthesis (34) , may be most beneficial later during TB treatment (7) when the acute phase response diminishes.
Three other trials in Indonesia (5), Malawi (12) , and Tanzania (10) examined the effects of micronutrient supplementation on TB treatment outcomes. The Indonesian and Tanzanian studies found no effects on weight or other anthropometric measurements, whereas the Malawian study did not report on these outcomes. The study in Indonesia supplemented 5000 IU (equivalent to 1.5 mg) of vitamin A and 15 mg of zinc for 6 mo, while that in Tanzania used multiple recommended dietary allowances of vitamins A, B complex, C, and E and selenium for a median of 40 mo. Considering that the supplementation periods in the 2 studies were longer than in our study, the absence of micronutrients other than zinc and vitamin A in the Indonesian study and zinc, copper, and vitamin D in the Tanzanian study and the differences in dosages may account for the lack of effects on weight or other anthropometric indicators in the 2 studies. Both zinc and vitamin D are essential for immunity, but zinc is also crucial for appetite (35) and synthesis of lean tissues (36) .
Our finding of a significant increase in handgrip strength among HIV2 TB patients on a multi-micronutrient supplement is similar to the results of a study in Singapore (9) . In this study, energy-protein supplementation among HIV2 TB patients increased handgrip strength after 6 wk of supplementation. However, unlike our study, the increase seemed to be mediated through an increase in lean mass. Thus, the seeming lack of corresponding increase in lean mass in our study suggests that the handgrip strength increment was probably due to improved muscle functions alone (37) . Handgrip strength is a proxy for work capacity (38) and therefore the increment may result in improved productivity (39, 40) , including ability to produce and procure food.
Unlike our earlier trial (7, 32) , the effects on weight in the current trial were modified by HIV infection, resulting in positive effects among HIV2 patients and negative effects among those co-infected with HIV. Any effect of a multi-micronutrient intervention on weight is likely to be mediated through energy intake or energy expenditure. Consequently, the interaction with HIV status must be due to the multi-micronutrient intervention increasing energy intake or decreasing energy expenditure among the HIV-uninfected patients and vice versa among the HIV-infected patients. We see 4 possible explanations. First, the multi-micronutrient content in the biscuits may have led to increased energy intake among HIV-uninfected patients and reduced intake among HIV-infected patients. Though the multimicronutrient and control supplements looked similar, their taste and smell were slightly different. Thus, it is possible that the multi-micronutrient content of the biscuits increased appetite and hence energy intake among the HIV-uninfected patients, but, because HIV-infected patients often have taste and smell complaints (41) , it could have reduced the intake of the biscuits. Our data does not suggest that supplement intake was lower in the multi-micronutrient group. However, appetite was reported to be lower in the multi-micronutrient compared to the control group among the HIV-infected patients, whereas the opposite was seen among HIV-uninfected patients, although this was only found at 5 mo (data not shown). Second, the multi-micronutrient supplement could have increased energy expenditure in those with HIV co-infection. This could have occurred, if multimicronutrient supplementation led to an improvement in muscle functions leading to an increase in physical activity. This possibility cannot be excluded, although our estimates of the multimicronutrients effects on handgrip strength among HIV-infected patients do not support this explanation. Third, the multimicronutrients provided may have impaired the bioavailability or metabolism of drugs (42, 43) , leading to delayed recovery, reduced energy intake, and/or increased resting energy expenditure. However, such micronutrient-drug interactions would explain our findings only if it affected the efficacy of HIV drugs. But because only 27 (11%) and 54 (22%) of the HIV-infected patients were receiving antiretroviral therapy at the beginning and during supplementation, respectively, this is not likely to be an explanation. Fourth, one or several of the multi-micronutrients provided could have enhanced HIV progression (44) or led to increased morbidity from either infectious or noninfectious causes leading to reduced energy intake and/or increased resting energy expenditure. Such an effect on HIV progression would most probably be accompanied by a decrease in CD4 cell count among patients in the multi-micronutrient group (45) . However, we found no such effects on CD4 count. In contrast, the effect on comorbidities is more likely, because at both 2 and 5 mo, more patients in the multi-micronutrient compared to the control arm reported having fever within the previous 2 wk. Nevertheless, the effect of the micronutrient supplementation on weight was probably mediated by more than one mechanism.
At the end of 5 mo, patients in both arms of the 2 HIV subgroups had gained considerable weight, although all the gains were ;#50% of ;7-to 10-kg deficits found at the beginning of TB treatment (19, 20) . Thus, the modest gains even among the HIV2 subgroup, the group in which the experimental intervention seemed to be beneficial, may imply that the nutritional support offered was not optimal or may have required a longer duration.
The strengths of this trial were that it was randomized and double-blinded and the overall loss to follow-up was modest. Furthermore, despite of our failure to achieve the planned sample size due to slow recruitment pace, the study was large enough to detect clinically important differences in an overall analysis and among the HIV-uninfected subgroup with high power. In addition, our outcome measures included a functional outcome, i.e. handgrip strength, which is an important indicator of work capacity during TB recovery. However, we used only proxies in assessing body composition and did not have markers of energy intake or expenditure and in most of our patients, compliance was assessed using reported information. Future studies should use better methods and include mechanistic substudies to be able to fully explain the findings.
In conclusion, multi-micronutrient supplementation during TB treatment may increase weight and handgrip strength among HIV2 PTB patients and may be recommended for TB programs. However, the same intervention was not found to be beneficial for HIV+ PTB2 patients. More research is needed to optimize the intervention for HIV2 PTB patients and to develop a nutrition intervention that is beneficial to HIV+ PTB2 patients with respect to accumulation of lean body mass, functional outcomes, and survival. Acknowledgments H.F., N.R., J.C., and A.B.A. conceived the study; G.P. and K.J. coordinated the implementation of the study; and G.P. analyzed the data and wrote the first draft of the manuscript. All authors contributed to the data collection and interpretation of results and commented on drafts. All authors read and approved the final manuscript.
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